Aeterna Zentaris has signed a co-development and profit sharing agreement with Ergomed Clinical Research for AEZS-108 in endometrial cancer.
Ergomed has been selected as the contract clinical development organization to conduct the Phase 3 trial with AEZS-108 in endometrial cancer.
As per the agreement, Ergomed will assume 30% of the clinical and regulatory costs for the Phase 3 trial with AEZS-108 in endometrial cancer.
Ergomed will receive its return on investment based on an agreed single digit percentage of any net income received by Aeterna Zentaris for AEZS-108 in this indication, up to a specified maximum amount.
Aeterna Zentaris president and CEO Juergen Engel said that the company is looking forward to work with Ergomed, which has a proven track record of delivering cost effective and efficient drug development services worldwide.
"This agreement is part of our non-dilutive strategy aimed at minimizing R&D costs while maximizing drug development efficiency," Engel added.
"Our goal for AEZS-108 with this collaboration is to provide a much needed new treatment option to women with late-stage endometrial cancer."
